Published in Clin Endocrinol (Oxf) on January 01, 2004
Influence of nCPAP on Metabolic Consequences Associated With OSAS | NCT00435643
Insulin and insulin resistance. Clin Biochem Rev (2005) 1.57
Impact of sleep and its disturbances on hypothalamo-pituitary-adrenal axis activity. Int J Endocrinol (2010) 1.11
Sleep Apnea and Metabolic Dysfunction: Cause or Co-Relation? Sleep Med Clin (2007) 1.04
Chronic intermittent hypoxia sensitizes acute hypothalamic-pituitary-adrenal stress reactivity and Fos induction in the rat locus coeruleus in response to subsequent immobilization stress. Neuroscience (2008) 1.03
Neuroendocrine alterations in obese patients with sleep apnea syndrome. Int J Endocrinol (2010) 1.01
Is obstructive sleep apnea associated with cortisol levels? A systematic review of the research evidence. Sleep Med Rev (2011) 0.93
Sleep apnea is related to the atherogenic phenotype, lipoprotein subclass B. J Clin Sleep Med (2012) 0.81
Interactions between sleep, stress, and metabolism: From physiological to pathological conditions. Sleep Sci (2015) 0.81
Changes in pituitary function with ageing and implications for patient care. Nat Rev Endocrinol (2013) 0.79
Neurogenic mechanisms underlying the rapid onset of sympathetic responses to intermittent hypoxia. J Appl Physiol (1985) (2015) 0.78
Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab (2010) 0.78
Evaluation of Anthropometric and Metabolic Parameters in Obstructive Sleep Apnea. Pulm Med (2015) 0.75
Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology (2001) 6.55
Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain (2002) 4.05
Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain (2005) 3.99
Protein p38: an integral membrane protein specific for small vesicles of neurons and neuroendocrine cells. J Cell Biol (1986) 3.68
Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet (2001) 3.64
Synaptobrevin: an integral membrane protein of 18,000 daltons present in small synaptic vesicles of rat brain. EMBO J (1989) 3.44
Artificial nutrition after major abdominal surgery: impact of route of administration and composition of the diet. Crit Care Med (1998) 3.08
Protein composition of the intranuclear inclusions of FXTAS. Brain (2005) 2.95
Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition. Crit Care Med (2001) 2.56
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet (2004) 2.33
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet (1999) 2.26
Lithium deintercalation in LiFePO4 nanoparticles via a domino-cascade model. Nat Mater (2008) 2.15
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab (2001) 2.13
Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest (2002) 2.09
Distribution of microtubule-associated protein 2 in the nervous system of the rat studied by immunofluorescence. Neuroscience (1984) 2.04
Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial. Arch Surg (1999) 1.97
Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab (2000) 1.83
Helicobacter pylori seropositivity in myocardial infarction. Lancet (1995) 1.81
FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology (2007) 1.80
Exacerbation of motor tic and induction of new tic by haloperidol use. West J Med (1992) 1.78
Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology (2007) 1.77
Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J Med Genet (2004) 1.77
The process of microbial translocation. Ann Surg (1990) 1.69
Aging in individuals with the FMR1 mutation. Am J Ment Retard (2004) 1.68
Synapsin I in nerve terminals: selective association with small synaptic vesicles. Science (1984) 1.67
Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med (2000) 1.62
Low dose (1 microg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. Clin Endocrinol (Oxf) (2000) 1.60
Cloning and localization of a conventional kinesin motor expressed exclusively in neurons. Neuron (1994) 1.57
Altered microperfusion at the rectal stump is predictive for rectal anastomotic leak. Dis Colon Rectum (2000) 1.55
Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology (2006) 1.55
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest (2006) 1.52
Immunonutrition in gastric cancer surgical patients. Nutrition (1999) 1.49
"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int (1996) 1.49
Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine (2013) 1.48
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. Clin Endocrinol (Oxf) (1999) 1.48
Isolated pulmonary infection acts as a source of systemic tumor necrosis factor. Crit Care Med (1994) 1.47
Circulating ghrelin levels in the newborn are positively associated with gestational age. Clin Endocrinol (Oxf) (2004) 1.44
Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest (2000) 1.44
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. J Endocrinol Invest (2003) 1.43
Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity. J Endocrinol Invest (1994) 1.42
B-type natriuretic peptide levels and insulin resistance in patients with severe ischemic myocardial dysfunction. J Endocrinol Invest (2009) 1.42
Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav (2012) 1.41
Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab (2004) 1.40
Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns? J Endocrinol Invest (2002) 1.40
Evaluation of the predictive performance of nutritional indicators by receiver-operating characteristic curve analysis. JPEN J Parenter Enteral Nutr (1992) 1.39
ACROSTUDY: the Italian experience. Endocrine (2014) 1.38
Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond. Clin Genet (2005) 1.37
Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab (2001) 1.37
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab (2001) 1.32
Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab (2004) 1.28
Neurological dysfunction associated with nonketotic hyperglycemia. Arch Neurol (1968) 1.26
Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett (1996) 1.25
Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol (2000) 1.24
Primary empty sella: Why and when to investigate hypothalamic-pituitary function. J Endocrinol Invest (2010) 1.21
Cerebral oedema complicating treated non-ketotic hyperglycaemia. Lancet (1969) 1.21
Sleep abnormalities in type 2 diabetes may be associated with glycemic control. Acta Diabetol (2008) 1.16
Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost (2007) 1.16
Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet (2010) 1.14
Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. Int J Obes Relat Metab Disord (1999) 1.11
Current management practices for acromegaly: an international survey. Pituitary (2011) 1.10
Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin Genet (2011) 1.08
Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis (2006) 1.08
Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int (1998) 1.07
Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis (1999) 1.07
Surgical treatment of gastric adenocarcinoma: impact on survival and quality of life. A prospective ten year study. Hepatogastroenterology (1996) 1.06
Free-living amoebae, a training field for macrophage resistance of mycobacteria. Clin Microbiol Infect (2009) 1.05
Complications of pancreatic surgery and the role of perioperative nutrition. Dig Surg (1999) 1.05
C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol (2012) 1.04
Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol (Oxf) (2005) 1.04
Regulated secretory pathways of neurons and their relation to the regulated secretory pathway of endocrine cells. Ann N Y Acad Sci (1987) 1.04
Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab (2011) 1.04
Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome. Clin Genet (2010) 1.04
Variability in FMRP and early development in males with fragile X syndrome. Am J Ment Retard (2001) 1.03
Circulating cytokine balance and activation markers of leucocytes in Q fever. Clin Exp Immunol (1999) 1.03
Superior sagittal sinus thrombosis and pulmonary embolism: a syndrome rediscovered. Acta Neurol Scand (1992) 1.01
Activation of epileptogenic foci by hyperosmolality. Neurology (1967) 1.00
Tissue heterogeneity of the FMR1 mutation in a high-functioning male with fragile X syndrome. Am J Med Genet (1999) 1.00
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest (2008) 0.99
Spastic paraparesis, cerebellar ataxia, and intention tremor: a severe variant of FXTAS? J Med Genet (2005) 0.98
Oral glucose load inhibits circulating ghrelin levels to the same extent in normal and obese children. Clin Endocrinol (Oxf) (2006) 0.98
Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance. Ann Surg (1994) 0.98
Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy. Clin Endocrinol (Oxf) (1990) 0.97
Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet (2012) 0.97
Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J Clin Endocrinol Metab (2000) 0.97
Training period in laparoscopic colorectal surgery. Surg Endosc (2001) 0.97
Feeding the gut early after digestive surgery: results of a nine-year experience. Clin Nutr (2002) 0.96
Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. J Clin Endocrinol Metab (2000) 0.96
Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol (2012) 0.96
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab (1998) 0.95
Distribution and survival of Escherichia coli translocating from the intestine after thermal injury. Ann Surg (1991) 0.95